Top ▲

CD22

Click here for help

Immunopharmacology Ligand  Target has curated data in GtoImmuPdb

Target id: 2786

Nomenclature: CD22

Abbreviated Name: SIGLEC2

Family: Other immune checkpoint proteins, CD molecules, SIGLECs (conserved)

Contents:

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 847 19q13.12 CD22 CD22 molecule
Previous and Unofficial Names Click here for help
B-lymphocyte cell adhesion molecule | sialic acid binding Ig-like lectin 2 | SIGLEC-2
Database Links Click here for help
Alphafold P20273 (Hs)
CATH/Gene3D 2.60.40.10
ChEMBL Target CHEMBL3218 (Hs)
Ensembl Gene ENSG00000012124 (Hs)
Entrez Gene 933 (Hs)
Human Protein Atlas ENSG00000012124 (Hs)
KEGG Gene hsa:933 (Hs)
OMIM 107266 (Hs)
Pharos P20273 (Hs)
RefSeq Nucleotide NM_001771 (Hs)
RefSeq Protein NP_001762
UniProtKB P20273 (Hs)
Wikipedia CD22 (Hs)

Download all structure-activity data for this target as a CSV file go icon to follow link

Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Value Parameter Reference
inotuzumab ozogamicin Peptide Approved drug Primary target of this compound Immunopharmacology Ligand Hs Binding 9.7 pKd 2
⤷ pKd 9.7 (Kd 2x10-10 M) [2]
moxetumomab pasudotox Peptide Approved drug Primary target of this compound Immunopharmacology Ligand Hs Binding 8.2 pKd 1,4-5
⤷ pKd 8.2 (Kd 6x10-9 M) [1,4-5]
Antibody Comments
Triphase Accelerator and Catalent Biologics are collaborating on the development of TRPH-222 (CAT-02-106) which is an anti-CD22 ADC whose cytotoxic maytansinoid payload is attached using the protease-resistant SMARTag® linker technology [3]. This technology allows a higher drug-to-antibody ratio and enhances the therapeutic index. TRPH-222 has advanced to clinical evaluation for relapsed and/or refractory B-cell NHL (NCT03682796).
Immunopharmacology Comments
CD22 (SIGLEC2) is a B cell I-type (Ig-type) lectin that binds glycans containing sialic acids. It is involved in adhesion and activation, mediates B cell-B cell interactions and may be involved in the localisation of B cells in lymphoid tissues. Most SIGLECs inhibit immune cell activation, via immunoreceptor tyrosine-based inhibitory (ITIM) motifs in their cytosolic domains. Hence, blockade of SIGLEC interactions restores immune cell activation, which is of interest for the treatment of B cell malignancies. CD22 is the target of the approved monoclonal antibody-drug conjugate (ADC) inotuzumab ozogamicin (FDA approved for ALL in 2017) and investigational ADC moxetumomab pasudotox.
Cell Type Associations
Immuno Cell Type:  B cells
Cell Ontology Term:   B cell (CL:0000236)
Immuno Process Associations
Immuno Process:  Antigen presentation
Immuno Process:  B cell (activation)
Immuno Process:  Cellular signalling
Immuno Process:  Immune regulation

References

Show »

1. Beers R, Kreitman RJ, Pastan IH, Salvatore G. (2003) Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells. Patent number: WO2003027135. Assignee: Beers R, Kreitman RJ, Pastan IH, Salvatore G, US Gov Health & Human Serv. Priority date: 26/09/2001. Publication date: 03/04/2003.

2. DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, Kunz A, Hamann PR, Gorovits B, Udata C et al.. (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood, 103 (5): 1807-14. [PMID:14615373]

3. Drake PM, Carlson A, McFarland JM, Bañas S, Barfield RM, Zmolek W, Kim YC, Huang BCB, Kudirka R, Rabuka D. (2018) CAT-02-106, a Site-Specifically Conjugated Anti-CD22 Antibody Bearing an MDR1-Resistant Maytansine Payload Yields Excellent Efficacy and Safety in Preclinical Models. Mol Cancer Ther, 17 (1): 161-168. [PMID:29142069]

4. Kreitman RJ, Pastan I. (2011) Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res, 17 (20): 6398-405. [PMID:22003067]

5. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I. (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol, 30 (15): 1822-8. [PMID:22355053]

How to cite this page

Other immune checkpoint proteins: CD22. Last modified on 15/01/2024. Accessed on 19/04/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=2786.